AUPH stock falls even as at H.C. Wainwright defends after key resignations (NASDAQ:AUPH)
seekingalpha.com
finance
2022-10-21 19:30:47

pcess609 Just a day after a ~13% rise, Canadian biotech Aurinia Pharmaceuticals (NASDAQ:AUPH) is back in the red even as H.C. Wainwright moved to address questions surrounding the departures of the company's Chief Medical Officer and Executive Vice President of Research. The resignation of medical chief Neil Solomons and research EVP Robert Huizinga was not due to any disagreement with the company management, the analyst Ed Arce remarked, citing AUPH's Chief Executive Peter Greenleaf. "After speaking with CEO Peter Greenleaf, we are confident that their leaving does not involve any disagreements with the company or management," the analyst wrote, reiterating the Buy rating and $26 per share target on the stock.
